posted
Looks like it may be a good time to accumulate - There as been a gentle and general upslope for the past four weeks. - - DD and Good Luck!
The Immune Response Corporation (IMNR) - Wednesday's shares closed down 3.11% to $0.0218. 5,245,489 shares were traded. The Immune Response Corporation announced on July 24th that IncreMental Advantage, an equity research firm, initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience. IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials."
The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
-------------------- Patience - works best with non-penny stocks Posts: 108 | From: Seattle | Registered: Oct 2005
| IP: Logged |
IncreMental Advantage, an equity research firm, has initiated coverage of The Immune Response Corporation (OTCBB: IMNR) with an Accumulate rating.
“The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials”
“We believe the Company’s clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding gives a valuation of $0.08 to $0.09 per share
... When the current stock price is compared with the potential from the company’s products, its equity seems almost like a non-expiring option on the trials. We believe these factors make IMNR an undervalued stock.”
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
Now that i think about it i just traded this like 3 months ago from . 07 to like .15 then they uped the share count and it fell like a rock.lol .01s
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
LOL the volume is so impressive that i think not only shakerz is on it
well the target at .08 is not so crazy if you see that there is also a gap at .065 to be closed
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
IMNR.ob --STRONG BUY --WIN 1000% ----- Robert LeBoyer, who has more than 14 years of Wall Street experience. Prize Target 0.09 cents . Big announce soon . Start Phase 3 !!!! The Immune Response Corporation (OTCBB: IMNR) - The Immune Response Corporation announced on July 24th that IncreMental Advantage, an equity research firm, initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience. IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials." The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
-------------------- please dont trade stocks on my alerts, do your dd first. Posts: 5265 | From: Alberta | Registered: Jan 2006
| IP: Logged |
posted
The insider buying is interesting and would lead you to believe something is in the works. If you look deeper you will see they started a stock match plan right before insiders started buying. This means for every one share they buy they get another share free. Imagine buying 50k worth of stock and then waiting 6 months and selling it for 100k...
Plan went into effect june 15th and buying started the 20th...
Worst case in my opinion is they hype the crap out of the treatments they have in development and when price rises they all sell and bring the share price crashing down again.
-------------------- If you made money, it was a good trade Posts: 453 | From: Cleveland, Ohio | Registered: Apr 2005
| IP: Logged |
posted
IMNR.ob --STRONG BUY --WIN 1000% ----- Insiders Buying ----RSI STRONG buy ----- 30 DAYS IN SHO LIST shorters need to Cover ------ VOLUME picking UP ------ NEW excelent CEO !!!!!!!
IMNR.ob --STRONG BUY --WIN 1000% ----- Robert LeBoyer, who has more than 14 years of Wall Street experience. Prize Target 0.09 cents . Big announce soon . Start Phase 3 !!!! The Immune Response Corporation (OTCBB: IMNR) - Wednesday's shares closed down 3.11% to $0.0218. 5,245,489 shares were traded. The Immune Response Corporation announced on July 24th that IncreMental Advantage, an equity research firm, initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience. IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials." The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
---------------------------------
LLama Gratis a cualquier PC del Mundo. Llamadas a fijos y móviles desde 1 céntimo por minuto. http://es.voice.yahoo.com
[Non-text portions of this message have been removed]
__._,_.___ Messages in this topic (66) Reply (via web post) | Start a new topic Messages | Files | Photos | Links | Database | Polls | Members | Calendar
You are receiving Individual Emails Change Delivery Settings Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe Recent Activity 11New Members Visit Your Group SPONSORED LINKS Business finance uk Business finance course Business finance online course Business finance class Small business finance Ads on Yahoo! Learn more now.
posted
IMNR.ob ---- NEW CEO --------Dr. Joseph O’Neill comes to The Immune Response Corporation ,After leading federal AIDS policy at the White House
After leading federal AIDS policy at the White House; the Office of the U.S. Secretary of Health and Human Services; and, the Office of the Global AIDS Coordinator at the U.S. Department of State. These positions, which were instrumental in formulating AIDS policy, have given him extensive experience and knowledge of the HIV/AIDS epidemic, its treatments, and the challenges for future treatments. Dr. O’Neill brings important relationships with drug development sponsors and researchers, as well as valuable experience
posted
From ********* online stock analyst: risk/reward looks very good here and volume is impressive: View the ********* Profile for The Immune Response Corporation:
IMNR - The Immune Response Corporation should experience a relief of recent valuation depression this week.
The overhang of 600MM warrants * $0.02 per share is virtually gone. The warrants expire on 8/7/06, and with 3-day settlement warrant-holders are no longer able to sell and exercise their warrants. This should relieve enormous pressure from the stock. The financing has been absorbed. The next set of warrants do not become exercisable until October 16 through November 30.
Posts: 660 | From: california | Registered: Nov 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
